Profile data is unavailable for this security.
About the company
Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
- Revenue in USD (TTM)81.75m
- Net income in USD-46.47m
- Incorporated1996
- Employees160.00
- LocationRigel Pharmaceuticals Inc1180 Veterans BlvdSOUTH SAN FRANCISCO 94080-1985United StatesUSA
- Phone+1 (650) 624-1100
- Fax+1 (650) 624-1101
- Websitehttps://www.rigel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urovant Sciences Ltd | 0.00 | -109.64m | 396.45m | 39.00 | -- | 16.61 | -- | -- | -3.62 | -3.62 | 0.00 | 0.7819 | 0.00 | -- | -- | 0.00 | -223.03 | -- | -344.03 | -- | -- | -- | -- | -- | -- | -79.60 | 0.6465 | -- | -- | -- | -200.65 | -- | -- | -- |
| Osmotica Pharmaceuticals PLC | 245.82m | -350.08m | 397.50m | 466.00 | -- | 2.49 | -- | 1.62 | -9.15 | -9.15 | 5.43 | 2.72 | 0.3643 | 4.73 | 4.61 | 527,503.60 | -51.88 | -- | -60.60 | -- | 49.14 | -- | -142.42 | -- | 1.78 | -0.7282 | 0.6544 | -- | 7.31 | -- | -165.90 | -- | -- | -- |
| AnaptysBio Inc | 5.00m | -94.07m | 397.78m | 78.00 | -- | 0.9438 | -- | 79.56 | -3.49 | -3.49 | 0.1854 | 15.53 | 0.0103 | -- | 1.93 | 64,102.56 | -19.30 | -13.42 | -20.36 | -14.43 | -- | -- | -1,881.34 | -150.34 | -- | -- | 0.0073 | -- | -50.00 | -1.83 | -105.04 | -- | 95.73 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -85.36m | 406.13m | 62.00 | -- | 3.84 | -- | -- | -3.83 | -3.83 | 0.00 | 4.53 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -54.30 | -- | -- | -- |
| Atreca Inc | 0.00 | -59.36m | 407.71m | 102.00 | -- | 2.52 | -- | -- | -2.19 | -2.19 | 0.00 | 7.33 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -37.83 | -- | -- | -- |
| Fast Line Holding Inc | 0.00 | -342.94k | 411.93m | -- | -- | -- | -- | -- | -0.0033 | -0.0033 | 0.00 | -0.0023 | 0.00 | -- | -- | -- | -68.89 | -- | -380.60 | -- | -- | -- | -- | -- | -- | -2,906.58 | 2.83 | -- | -- | -- | 89.79 | -- | -- | -- |
| Progenics Pharmaceuticals, Inc. | 23.10m | -71.98m | 413.96m | 79.00 | -- | 7.40 | -- | 17.92 | -0.8452 | -0.8452 | 0.2713 | 0.6473 | 0.1479 | -- | 3.85 | 292,379.80 | -46.08 | -18.78 | -52.20 | -20.44 | 59.61 | -- | -311.63 | -97.69 | -- | -33.81 | 0.4225 | -- | 33.54 | 14.72 | -23.66 | -- | 42.92 | -- |
| Rigel Pharmaceuticals, Inc. | 81.75m | -46.47m | 417.35m | 160.00 | -- | 6.06 | -- | 5.11 | -0.2777 | -0.2777 | 0.489 | 0.4111 | 0.5855 | 1.07 | 11.03 | 517,373.40 | -33.28 | -54.09 | -40.67 | -64.53 | 98.88 | -- | -56.84 | -338.02 | 4.03 | -- | 0.1244 | -- | 892.62 | 44.15 | 9.63 | -- | -1.96 | -- |
| SIGA Technologies, Inc. | 24.05m | 49.65m | 421.59m | 41.00 | 8.38 | 4.10 | 8.42 | 17.53 | 0.6202 | 0.6202 | 0.2943 | 1.27 | 0.1387 | 0.5133 | 10.11 | 586,520.00 | 28.64 | 4.47 | 30.12 | 4.69 | 92.70 | -- | 206.48 | 7.42 | 8.03 | -0.3433 | 0.4341 | -- | 3,788.30 | 143.97 | 1,183.35 | -- | -34.64 | -- |
| Dynavax Technologies Corporation | 29.97m | -159.08m | 423.52m | 249.00 | -- | 10.82 | -- | 14.13 | -2.40 | -2.40 | 0.4495 | 0.4669 | 0.1115 | 0.7183 | 5.80 | 120,349.40 | -57.99 | -63.29 | -67.82 | -72.65 | 37.91 | -- | -519.95 | -1,627.74 | 4.09 | -11.84 | 0.8194 | -- | 2,407.03 | -6.14 | -66.99 | -- | 56.28 | -- |
| Aptorum Group Ltd | 596.58k | -18.43m | 424.78m | 39.00 | -- | 17.03 | -- | 712.03 | -0.1303 | -0.1303 | 0.021 | 0.859 | 0.018 | 35.40 | 1.28 | 15,296.92 | -58.12 | -- | -77.17 | -- | -11.72 | -- | -3,224.87 | -- | 12.91 | -1.98 | 0.0069 | -- | -- | -- | -482.22 | -- | -- | -- |
| BioSpecifics Technologies Corp. | 36.28m | 23.30m | 425.39m | 5.00 | 18.29 | 3.64 | 17.76 | 11.73 | 3.17 | 3.17 | 4.94 | 15.93 | 0.3422 | -- | 2.25 | 7,255,512.00 | 21.98 | 20.90 | 22.26 | 21.46 | -- | -- | 64.23 | 47.08 | -- | -- | 0.00 | 0.00 | 20.11 | 17.96 | 61.35 | 30.56 | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 35.50m | -62.18m | 430.72m | 77.00 | -- | 14.53 | -- | 12.13 | -1.02 | -1.02 | 0.5632 | 0.4583 | 0.549 | -- | -- | 461,004.50 | -96.17 | -93.35 | -151.96 | -122.99 | -- | -- | -175.17 | -1,216.46 | -- | -- | 0.00 | -- | 97.62 | -- | -71.71 | -- | -- | -- |
| Beyondspring Inc | 0.00 | -38.13m | 431.76m | 52.00 | -- | 19.64 | -- | -- | -1.62 | -1.62 | 0.00 | 0.7886 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -159.57 | 0.0591 | -- | -- | -- | 40.21 | -- | -- | -- |
| Voyager Therapeutics Inc | 73.73m | -53.55m | 435.98m | 123.00 | -- | 4.00 | -- | 5.91 | -1.63 | -1.63 | 2.10 | 2.94 | 0.2572 | -- | -- | 599,390.30 | -18.68 | -34.85 | -23.13 | -38.94 | -- | -- | -72.64 | -497.22 | -- | -- | 0.00 | -- | -24.82 | -- | -24.88 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 6.34m | -114.66m | 436.05m | 281.00 | -- | 12.82 | -- | 68.83 | -1.18 | -1.18 | 0.0649 | 0.3402 | 0.0434 | -- | 3.51 | 22,544.70 | -78.96 | -39.71 | -95.28 | -49.23 | -- | -- | -1,821.08 | -203.75 | -- | -19.61 | 0.6599 | -- | -27.80 | 17.75 | -9.93 | -- | 63.78 | -- |
Data as of Jan 28 2020. Currency figures normalised to Rigel Pharmaceuticals Inc's reporting currency: US Dollar USD
58.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2019 | 23.33m | 13.92% |
| Wellington Management Co. LLPas of 30 Sep 2019 | 22.00m | 13.13% |
| BlackRock Fund Advisorsas of 30 Sep 2019 | 13.07m | 7.80% |
| Millennium Management LLCas of 13 Nov 2019 | 8.76m | 5.22% |
| The Vanguard Group, Inc.as of 30 Sep 2019 | 8.00m | 4.77% |
| Tamarack Advisers LPas of 30 Sep 2019 | 5.48m | 3.27% |
| Invesco Advisers, Inc.as of 30 Sep 2019 | 5.00m | 2.98% |
| Rock Springs Capital Management LPas of 30 Sep 2019 | 4.20m | 2.51% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 2019 | 3.81m | 2.28% |
| Citadel Advisors LLCas of 30 Sep 2019 | 3.76m | 2.24% |
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
